SMi’s 3rd Annual Biobanking Event Creates A Buzz In The World Of Biobanking, 24-25 June 2013, London
SMi’s much anticipated 3rd Biobanking conference returns on 24th-25th May and is already proving to be very popular with esteemed industry professionals.
“Use of human biosamples is critical in enabling the discovery and validation of new targets and biomarkers” Paul Whittaker, Director, Novartis – SPEAKER AT BIOBANKING 2013
“Biobanking has propelled research and researchers in a new era where innovation, reciprocity and universalism meet”…. – Ma’n H. Zawati, Academic Associate, Centre of Genomics and Policy, McGill University – SPEAKER AT BIOBANKING 2013
In a first-of-its kind national survey published earlier this year by Genome Medicine, nearly 70% of the 456 US biobankers questioned, are worried that specimen samples are being underused. Nature Medicine Journel With this in mind it is now more important than ever to build sustainable biobanks having improved access and longer bio-specimen lifecycles. In addition to the concerns of retention, biobanks are under constant pressure to meet quality standards and international regulations.
The ultimate success of biobanking will depend on overcoming both major technical and ethical challenges. This event aims to inform and guide delegates to overcome these challenges and enable them to understand and share best practice.
OTHER FEATURED SPEAKERS WILL INCLUDE:
- Julie Corfield, Director, Areteva
- Janine Swifka, Biobank Scientist, Bayer
- Shaun Griffin, Director of Communications, HRA & HTA
- Kristof Van Quathem, Data Protection Advisor, Covington & Burling LLP
- Kirstin Goldring, Biobank Facilitator, UCL Biobank
For further information on the conference contact John Collins on email [email protected] or call +44 (0)20 7827 6734
SMi Group Ltd